F Prime, Inc.

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it is part of the legacy of Fidelity Investments, one of the largest asset management firms in the world. F Prime focuses on investing in North American and European companies across various sectors, including healthcare, life sciences, medtech, technology, and health information technology. The firm operates several specialized funds, such as those dedicated to healthcare and life sciences, which aim to support early-stage companies in these industries. With a commitment to fostering entrepreneurship, F Prime leverages its extensive insights, domain expertise, and relationships to assist entrepreneurs in building impactful companies, all while avoiding the pressures of external fundraising.

Abdul Abdirahman

Senior Associate

Sanjay Aggarwa

Venture Partner

Sanjay Aggarwal

Venture Partner

Jessica Alston

Partner

Nikhil Ananth

Associate

Renée Anderson

VP of Finance

Hannah Arnold

Venture Partner

Carl Byers

Partner

Kevin Chu

Principal

Brett Cook

Partner

Jay Farber

Venture Partner

Shervin Ghaemmaghami

Partner

Stephen Knight

President & Senior Managing Partner

Sarah Lamont

Associate

Erica Lee

Associate

Connie Li

Principal

Jon Lim

PARTNER

John Lin

Principal

Muzammil Mansuri Ph.D

Venture Partner

Betsy Mulé

Associate

Alexander Pasteur Ph.D

Partner

Ketan Patel

Partner

Mary Bevelock Pendergast

Partner

John Raguin

Venture Partner

Steve Schultz

Venture Partner

Siyu Shi

Associate

Nihal Sinha

Partner

Anastasiya Sybirna

Associate

Martin Taylor

Senior Associate

Gaurav Tuli

Partner

Robert Weisskoff

Partner

Alex Wong

Associate

Rocio Wu

Principal

Chong Xu

Partner

Brian Yordy

Principal

Tristan Zajonc

Venture Partner

Past deals in Growth Stage

1upHealth

Series C in 2023
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, that specializes in health data aggregation and centralization. Founded in 2017, the company offers a platform that secures data transmission between health systems and consumer applications. This platform consolidates health data from various electronic medical record systems into a digital health record controlled by the user, facilitating seamless sharing with healthcare providers. It also enables providers to access and query the most current patient data across multiple connected health systems. Additionally, 1upHealth's platform supports developers in obtaining clinical data from various clinics and hospitals, promoting better healthcare outcomes and cost reduction through enhanced data accessibility.

Canoe

Series B in 2023
Canoe Software Inc. develops an artificial intelligence-based software solution for financial document and data management, primarily targeting allocators and investors in alternative assets. Founded in 2013 and based in New York, the company specializes in automating the collection, organization, and categorization of investment documents. Its software enables users to extract unstructured data from these documents and integrate it into various accounting and reporting platforms, enhancing data accuracy and operational efficiency. Canoe’s services cater to a diverse clientele, including single and multi-family offices, endowments, foundations, pensions, investment consultants, wealth managers, and financial institutions. By transforming PDF reports into actionable data, Canoe aims to improve the post-investment operational, monitoring, and reporting experience for its clients.

Vendr

Series B in 2022
Vendr, Inc. is a Boston-based company that provides a software-as-a-service solution designed to manage the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr specializes in commercial negotiations, renewal management, and contract logistics, enabling companies to streamline their software acquisition efforts. By assisting organizations in purchasing and renewing software, Vendr helps them save both time and money, making it an essential partner for scaling companies. Its services are utilized by a range of fast-growing business-to-business and business-to-consumer companies, highlighting its effectiveness in the software procurement landscape.

Proximie

Series C in 2022
Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

RightHand Robotics

Series C in 2022
RightHand Robotics, Inc. specializes in manufacturing robotic order-picking systems designed for various industrial applications, including e-commerce, food handling, and flexible manufacturing. The company offers innovative products such as the ReFlex SF, which features a 3D-printed palm equipped with servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that enhances the robots' ability to grasp items gently and make adjustments to avoid errors. Their technology allows robots to automatically grasp a wide range of items from bins and cases, eliminating the need for extensive data-entry or parameter-tuning, thereby making the systems cost-effective and adaptable to the evolving needs of businesses. Founded in 2015, RightHand Robotics is headquartered in Cambridge, Massachusetts, with a sales and business development office located in Frankfurt, Germany.

Equip Health

Series B in 2022
Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Logixboard

Series B in 2022
Logixboard, Inc. is a Seattle-based company founded in 2016 that offers a cloud platform designed to enhance transparency and communication for freight forwarders. The platform addresses inefficiencies in the $2 trillion freight forwarding industry, where many firms rely on outdated methods such as paper, spreadsheets, and email for tracking shipments. By integrating with existing back-office applications, Logixboard's solution serves as a digital customer engagement layer, enabling freight forwarders to streamline their operations and improve customer service. The platform empowers companies to manage and control their freight operations more effectively, ultimately reducing costs and increasing efficiency in a traditionally low-tech industry.

Leyden Labs

Series B in 2022
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Papaya

Series B in 2021
Papaya is a developer of an online mobile bill payment application that simplifies financial transactions for users. The application supports various payment methods, including debit and credit cards and direct bank account transfers. It prioritizes security by encrypting personal information and payment data, ensuring compliance with HIPAA and PCI standards. In addition to its bill payment services, Papaya operates as an electronic money platform, offering digital solutions, online banking, and international payment services. This combination of features enables users to manage their financial activities efficiently and securely.

Lighthouse

Series B in 2021
Lighthouse, operating under the name OTA Insight Ltd, specializes in providing cloud-based business intelligence solutions for the hospitality industry. Founded in 2012 and based in London, the company offers a suite of tools including Rate Insight, Parity Insight, and Revenue Insight, which help hoteliers make informed revenue and distribution decisions. These solutions utilize advanced data systems and forecasting algorithms to deliver real-time market demand forecasts, rate intelligence, and ranking analytics. With a strong emphasis on customer support, OTA Insight’s platform integrates seamlessly with various hotel management systems and data providers, supporting over 50,000 properties in 168 countries. Recognized as a leader in hospitality business intelligence, the company has garnered accolades and continues to empower hoteliers to optimize occupancy rates and enhance profitability.

AppliedVR

Series B in 2021
AppliedVR is a leader in therapeutic virtual reality, focusing on improving patient experiences in healthcare through innovative digital health solutions. Founded in 2013 and based in Los Angeles, the company provides a virtual reality platform designed for pain and anxiety management in various settings, including hospitals and surgery centers. AppliedVR has established strategic partnerships with prominent institutions such as Cedars-Sinai and Children's Hospital Los Angeles, and its solutions have been scientifically validated, impacting over 20,000 patients across more than 250 hospitals in eight countries. The company draws on extensive academic research and collaboration with leading medical experts to develop its digital wellness platform, which addresses both chronic and acute pain, as well as anxiety related to surgical and emergency procedures. Through its ongoing product development, AppliedVR aims to create a comprehensive digital pain management platform and redefine treatment approaches for pain management both in healthcare facilities and at home.

Notable

Series B in 2021
Notable is an AI-powered healthcare startup focused on enhancing physician-patient interactions by automating and digitizing the recording of medical visits. The company's platform utilizes natural language processing and voice recognition technology to automatically capture and structure conversations between doctors and patients, facilitating the seamless update of electronic health records. Additionally, Notable's system recommends appropriate billing codes, streamlining administrative tasks for healthcare providers. By improving the efficiency of these interactions, Notable aims to allow physicians to dedicate more time to patient care rather than paperwork.

Stride Health

Series C in 2021
Stride Health, Inc. operates a health benefits platform that allows independent workers and part-time employees to select and enroll in affordable health coverage. It offers dental plans, drive plans, and doctor and prescription insurance plans. The company serves customers in the United States. Stride Health, Inc. was formerly known as Covered, Inc. and changed its name to Stride Health, Inc. in March 2013. The company was incorporated in 2013 and is based in San Francisco, California.

Funnel

Series C in 2021
Funnel Operation AB designs and develops software/platform that helps marketers automate their data collection. The company's products include dashboards and reports which simplify marketing reporting and analysis; data studio connector which gets marketing data from a number of ad sources; Google analytics upload which automatically uploads cost data to Google analytics; API and connectors which collect advertising data and send it anywhere; and Google sheets upload which add all advertising data to Google sheets. It caters to e-commerce companies, media agencies, brands, b2b businesses, mobile apps, and gaming companies. Funnel Operation AB was founded in 2014 and is based in Stockholm, Sweden.

Centivo

Venture Round in 2021
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

NOCD

Series B in 2021
NOCD Inc. develops and operates a mobile application that connects mental health practitioners and people with obsessive compulsive disorder (OCD). Its application uses cognitive behavioral therapy techniques to assist in treating OCD patients. The company also helps OCD patients to find clinically supported treatment; and operates an online platform for OCD treatment. NOCD Inc. was founded in 2014 and is based in Chicago, Illinois.

Gyenno Science

Series B in 2021
Developer of intelligent medical devices designed for treatment of Parkinson and motor dysfunction. With research and development of intelligent monitoring and assistant devices, the company develops systematic systematic solutions to functional disorders for patients with Parkinson and motor dysfunction, enabling patients to monitor their physical activities and facilitate their movements.

Oviva

Series C in 2021
Oviva AG is a digital health company that specializes in providing medical nutritional counseling services in Switzerland, Germany, and the United Kingdom. Established in 2013 and based in Ingenbohl, Switzerland, the company offers treatment for various medical conditions, including obesity, diabetes, heart disease, and digestive disorders, through both in-person consultations in clinics and remote support. Oviva UK Limited, founded in 2015 and headquartered in London, focuses on digitally-enabled behavior change programs for diet and lifestyle-related health issues. The company has developed a smartphone application that enables clients to communicate with dietitians, maintain a photo food diary, monitor their health goals, and access personalized educational materials. This technology-enabled approach aims to improve health outcomes for patients while reducing healthcare costs by minimizing the need for in-clinic visits and preventing complications associated with chronic conditions.

Carrot Fertility

Series C in 2021
Carrot offers a fertility benefit for modern companies, focused on making fertility care easier, accessible, and more affordable. The company partners with modern companies to provide fertility coverage for the millions of employees. Through its software, Carrot helps employees to personalize a fertility plan, chat with fertility experts, order medications, and access unique content. It helps them access the care they need, such as egg freezing, in-vitro fertilization, fertility diagnoses, and more.

Innovusion

Series B in 2021
Innovusion is a leading developer of image grade LiDAR sensor systems for the level 4 and 5 of the autonomous vehicle and ADAS markets. Their unique combination of range, resolution, hardware accelerated sensor fusion, compact size, ease of integration and cost effectiveness makes our products the ideal choice for the most demanding applications. We are venture-backed and headquartered in the heart of Silicon Valley.

MoEngage

Series C in 2021
MoEngage, Inc. provides a user analytics and engagement platform to improve customer retention and lifetime values. Its platform enables user intelligence, push notification, in-app messaging, and smart triggering aspects. The company serves e-commerce, telecom, travel and hospitality, and banking and finance industries. MoEngage, Inc. has a strategic partnership with Vidora, Inc. The company was founded in 2014 and is based in San Francisco, California. It has additional offices in Bengaluru, India; Singapore; London, United Kingdom; Jakarta, Indonesia; Bangkok, Thailand; H? Chí Minh, Vietnam; and Berlin, Germany.

SonderMind

Series C in 2021
SonderMind Inc. provides mental health services through a digital network of therapists and care providers. Its solution connects consumers with a therapist for video telehealth or in-person sessions. Its service areas include ADHD, addiction, anorexia, anxiety, binge eating, bipolar disorder, bulimia, depression, eating disorders, grief and loss, LGBTQ, obsessive compulsive disorder (OCD), PTSD, postpartum, and schizophrenia. The company was founded in 2017 and is based in Denver, Colorado.

Embark

Series B in 2021
Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Castor

Series B in 2021
Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.

Pulmocide

Series C in 2021
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Affinia Therapeutics

Series B in 2021
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

CareStack

Series C in 2021
CareStack is a single all-in-one platform on the cloud that combines dental practice management, patient engagement, practice marketing, and data analytics. CareStack is currently used by large and growing practices as an all-in-one solution to increase productivity, minimize costs, and improve patient dental care. CareStack's mission is to help dentists to have a better practice and a better life. Through their technology-led offerings, CareStack will elevate dental offices to a higher degree of financial success.

Proximie

Series B in 2021
Proximie Inc., based in Bedford, Massachusetts, offers a secure software platform that facilitates virtual surgical collaboration among surgeons. By leveraging advanced telecommunication, augmented reality, artificial intelligence, and machine learning technologies, Proximie's platform enables real-time, peer-to-peer assistance during surgeries, regardless of location. This innovative approach allows surgeons to share expertise before, during, and after procedures, effectively overcoming the barriers of time and distance. Furthermore, the platform is compatible with various devices and software used in operating rooms, allowing for seamless integration and interaction. Proximie's mission is to enhance surgical knowledge and skills, enabling surgeons to refine their techniques in diverse settings, even with limited bandwidth.

1upHealth

Series B in 2021
1upHealth, Inc. is a health-tech company based in Boston, Massachusetts, that specializes in health data aggregation and centralization. Founded in 2017, the company offers a platform that secures data transmission between health systems and consumer applications. This platform consolidates health data from various electronic medical record systems into a digital health record controlled by the user, facilitating seamless sharing with healthcare providers. It also enables providers to access and query the most current patient data across multiple connected health systems. Additionally, 1upHealth's platform supports developers in obtaining clinical data from various clinics and hospitals, promoting better healthcare outcomes and cost reduction through enhanced data accessibility.

Zenflow

Series B in 2021
Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.

Firefly Health

Series B in 2021
Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, that specializes in primary health care services through an artificial intelligence-based platform. Founded in 2016, the company aims to redefine patient care by providing a virtual-first approach that combines advanced technology with a dedicated care team. Firefly Health offers services for common health conditions such as back pain, stomach flu, and women's health issues, facilitating live video appointments with primary care physicians without any membership fees. This model allows patients to navigate their health more effectively and make informed decisions, while enabling healthcare professionals to deliver consistent and proactive care.

OZiva

Series B in 2021
OZiva is a plant-based Clean Nutrition Brand. The brand’s core differentiator lies in building a nutrition & fitness ecosystem that combines the best of ancient sciences such as Ayurveda, modern micronutrients, and an instantaneous digital community altogether.

YS Biopharma

Series B in 2021
Yisheng Biopharma Co., Ltd., a biopharmaceutical company, researches, develops, manufactures, and markets immuno-oncology products and vaccines. It offers YS-ON-001, an investigational biological product that demonstrates immuno-modulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells for the treatment of advanced solid tumors. Yisheng Biopharma Co., Ltd. was founded in 2002 and is based in Beijing with operations in China, the United States, Cambodia, and Singapore.

Cohort

Series B in 2021
Cohort, Inc. develops software to transform chronic care management and clinical trials. The company’s clinical AI/NLP analyzes EHR, including diagnostics (normal, abnormal, and correlated), medications (labels), and clinical notes (free text) to surface context specific to the patient and condition. Its solution identifies and enrolls eligible patients, auto-generates care-plans, and automates compliance and billing operations. The company is based in New York, New York with an additional office in San Francisco, California.

Centivo

Series B in 2020
Centivo Corporation is a health plan administrator that provides innovative health insurance solutions for self-funded employers, employees, and clinicians. Founded in 2016 and based in Stamford, Connecticut, with additional offices in New York and Buffalo, the company aims to deliver high-quality, affordable healthcare by facilitating partnerships between employers and primary care teams. Centivo offers a comprehensive suite of services, including technology, claims processing, customer support, and population health management, to efficiently administer health benefits. Its model emphasizes collaboration between members and their primary care providers, encouraging cost-effective healthcare choices. Members benefit from personalized tools for patient-doctor matching and receive support through a user-friendly app and concierge services. Employers are supported by Centivo's commitment to eliminating waste and ensuring accountability in performance.

Odaseva

Series B in 2020
Odaseva is a unified cloud data protection, compliance, and operations platform for enterprises running Salesforce. The company delivers enterprise-class data governance, providing data protection (backup and recovery, archiving, governor limits monitoring), data compliance for regulation requirements such as GDPR and data operations (Salesforce DX data extensions). Odaseva was developed for Salesforce by Salesforce experts and is endorsed by Salesforce Ventures.

Snapdocs

Series C in 2020
Snapdocs, Inc. is a real estate technology company that provides a digital platform designed to streamline the mortgage closing process. Founded in 2012 and based in San Francisco, California, Snapdocs connects lenders, title and escrow companies, notary publics, and home buyers to enhance collaboration and efficiency in real estate transactions. The platform features advanced automation and standardized workflows, allowing participants to choose their preferred closing methods while improving accuracy and consumer satisfaction. It also enables notary signing agents to showcase their qualifications, helping them attract potential clients. By simplifying mortgage loan closings and improving the overall borrower experience, Snapdocs empowers its users to operate more effectively and transparently in a competitive market.

Carrot Fertility

Series B in 2020
Carrot offers a fertility benefit for modern companies, focused on making fertility care easier, accessible, and more affordable. The company partners with modern companies to provide fertility coverage for the millions of employees. Through its software, Carrot helps employees to personalize a fertility plan, chat with fertility experts, order medications, and access unique content. It helps them access the care they need, such as egg freezing, in-vitro fertilization, fertility diagnoses, and more.

Checkmate Pharmaceuticals

Series C in 2020
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

PatientPing

Series C in 2020
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.

NodThera

Series B in 2020
NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Founded in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome, a multi-protein complex involved in the body's immune response. NodThera aims to address a variety of inflammatory and neuroinflammatory diseases, including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. Through its innovative approach to inflammasome research, NodThera seeks to contribute to the advancement of therapeutic options for these conditions.

Avalyn Pharma

Series B in 2020
Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Rallybio

Series B in 2020
Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

SonderMind

Series B in 2020
SonderMind Inc. provides mental health services through a digital network of therapists and care providers. Its solution connects consumers with a therapist for video telehealth or in-person sessions. Its service areas include ADHD, addiction, anorexia, anxiety, binge eating, bipolar disorder, bulimia, depression, eating disorders, grief and loss, LGBTQ, obsessive compulsive disorder (OCD), PTSD, postpartum, and schizophrenia. The company was founded in 2017 and is based in Denver, Colorado.

Devoted Health

Series C in 2020
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Devoted Health

Series C in 2020
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

Xilio Therapeutics

Series B in 2020
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Whatfix

Series C in 2020
Quicko Technosoft Labs Private Limited (also known as Whatfix) is a digital adoption platform that helps enterprises and businesses simplify their training and support efforts with easily accessible contextual information. Its platform is built with real-time interactive guidance technology at its core which helps users achieve optimal performance by providing just-in-time guidance that enables them to perform tasks quickly and efficiently.

MoEngage

Series C in 2020
MoEngage, Inc. provides a user analytics and engagement platform to improve customer retention and lifetime values. Its platform enables user intelligence, push notification, in-app messaging, and smart triggering aspects. The company serves e-commerce, telecom, travel and hospitality, and banking and finance industries. MoEngage, Inc. has a strategic partnership with Vidora, Inc. The company was founded in 2014 and is based in San Francisco, California. It has additional offices in Bengaluru, India; Singapore; London, United Kingdom; Jakarta, Indonesia; Bangkok, Thailand; H? Chí Minh, Vietnam; and Berlin, Germany.

WelbeHealth

Series C in 2020
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

BenchSci

Series B in 2020
BenchSci's vision is to bring medicine to patients 50% faster by 2025. The company empowers scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science at 15 top 20 pharmaceutical companies and over 4,300 leading research centers worldwide. BenchSci is a CIX Top 10 Growth company, certified Great Place to Work®, and top-ranked company on Glassdoor.

Funnel

Series B in 2020
Funnel Operation AB designs and develops software/platform that helps marketers automate their data collection. The company's products include dashboards and reports which simplify marketing reporting and analysis; data studio connector which gets marketing data from a number of ad sources; Google analytics upload which automatically uploads cost data to Google analytics; API and connectors which collect advertising data and send it anywhere; and Google sheets upload which add all advertising data to Google sheets. It caters to e-commerce companies, media agencies, brands, b2b businesses, mobile apps, and gaming companies. Funnel Operation AB was founded in 2014 and is based in Stockholm, Sweden.

Oviva

Series B in 2020
Oviva AG is a digital health company that specializes in providing medical nutritional counseling services in Switzerland, Germany, and the United Kingdom. Established in 2013 and based in Ingenbohl, Switzerland, the company offers treatment for various medical conditions, including obesity, diabetes, heart disease, and digestive disorders, through both in-person consultations in clinics and remote support. Oviva UK Limited, founded in 2015 and headquartered in London, focuses on digitally-enabled behavior change programs for diet and lifestyle-related health issues. The company has developed a smartphone application that enables clients to communicate with dietitians, maintain a photo food diary, monitor their health goals, and access personalized educational materials. This technology-enabled approach aims to improve health outcomes for patients while reducing healthcare costs by minimizing the need for in-clinic visits and preventing complications associated with chronic conditions.

Wellframe

Series C in 2019
Wellframe is a hospital and healthcare it provides a digital health management solutions that include care management support, digital concierge solutions, and transformation services. It helps healthcare organizations by providing solutions that enable them to support people longitudinally between traditional clinical interactions. The company was founded in 2011 and headquartered in Boston, Massachusetts, United States.

Snapdocs

Series B in 2019
Snapdocs, Inc. is a real estate technology company that provides a digital platform designed to streamline the mortgage closing process. Founded in 2012 and based in San Francisco, California, Snapdocs connects lenders, title and escrow companies, notary publics, and home buyers to enhance collaboration and efficiency in real estate transactions. The platform features advanced automation and standardized workflows, allowing participants to choose their preferred closing methods while improving accuracy and consumer satisfaction. It also enables notary signing agents to showcase their qualifications, helping them attract potential clients. By simplifying mortgage loan closings and improving the overall borrower experience, Snapdocs empowers its users to operate more effectively and transparently in a competitive market.

CareStack

Series B in 2019
CareStack is a single all-in-one platform on the cloud that combines dental practice management, patient engagement, practice marketing, and data analytics. CareStack is currently used by large and growing practices as an all-in-one solution to increase productivity, minimize costs, and improve patient dental care. CareStack's mission is to help dentists to have a better practice and a better life. Through their technology-led offerings, CareStack will elevate dental offices to a higher degree of financial success.

Recurly

Series C in 2019
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.

Insilico Medicine

Series B in 2019
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.

Insilico Medicine

Series B in 2019
Insilico Medicine, Inc. is an artificial intelligence company based in Rockville, Maryland, specializing in drug discovery, biomarker development, and aging research. Founded in 2014, the company leverages advanced AI techniques, including generative adversarial networks and deep learning, to create novel molecular structures for various diseases. Insilico Medicine has developed a comprehensive end-to-end pipeline for drug discovery, which encompasses all stages from initial research to clinical trials. Its notable platforms include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, which integrates predictors of age. The company is actively engaged in internal drug discovery programs targeting conditions such as cancer, Alzheimer's disease, and diabetes. Additionally, Insilico Medicine has partnered with Life Extension to produce nutraceutical products using bioinformatics and deep learning. It serves a diverse clientele, including academia, pharmaceutical companies, and cosmetic firms, while also providing consumer-facing applications to enhance health and longevity.

Protenus

Series C in 2019
The Protenus healthcare compliance analytics platform uses artificial intelligence to audit every access to patient records for the nation’s leading health systems. Providing healthcare leaders full insight into how health data is being used, and alerting compliance teams to policy violations, Protenus helps our partner hospitals make decisions about how to better protect their data, their patients, and their institutions. Learn more at Protenus.com and follow us on Twitter @Protenus.

Radico

Series C in 2019
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.

Buoy Health

Series B in 2019
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

RiskLens

Series B in 2019
The leading provider of cyber risk management software, RiskLens empowers business executives, risk officers and CISOs to manage their organization's cyber risk from the business perspective by quantifying it in financial terms. RiskLens was founded in 2011 and is headquartered in Spokane, Washington.

ABK Biomedical

Series B in 2019
ABK Biomedical Inc. is a Canadian company founded in 2012, based in Halifax, that focuses on the development of embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company integrates clinical market insights with advanced biomaterials to enhance treatment options for patients undergoing embolization, a procedure utilized in interventional radiology. ABK Biomedical is committed to innovating and improving these medical procedures to provide better outcomes for patients suffering from these conditions.

Vestwell

Series B in 2019
Vestwell is a digital retirement platform founded in 2016 and based in New York, New York. The company simplifies the offering and administration of 401(k) plans by addressing common challenges faced by advisors, employers, and employees. Vestwell streamlines the process through seamless plan design, automated onboarding, and efficient administration, while also providing flexible investment strategies at competitive prices. By serving as a single point of contact, Vestwell modernizes retirement offerings, focusing on the best interests of both plan sponsors and participants.

Artemis Health

Series C in 2019
Artemis Health Inc. is a health data analytics company that focuses on providing self-insured employers with actionable insights into their benefits programs. The company operates a platform that enables users to identify issues within their benefits, share findings with stakeholders, and implement solutions to enhance their offerings while tracking the effectiveness of these solutions. Founded in 2013 and headquartered in Salt Lake City, Utah, Artemis Health aims to improve the healthcare system in the United States by empowering employers to leverage their own benefits data to reduce spending and enhance employee benefits.

Whatfix

Series B in 2019
Quicko Technosoft Labs Private Limited (also known as Whatfix) is a digital adoption platform that helps enterprises and businesses simplify their training and support efforts with easily accessible contextual information. Its platform is built with real-time interactive guidance technology at its core which helps users achieve optimal performance by providing just-in-time guidance that enables them to perform tasks quickly and efficiently.

Beam Therapeutics

Series B in 2019
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.

Singular Genomics

Venture Round in 2019
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.

Checkmate Pharmaceuticals

Series C in 2018
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Genomics

Series B in 2018
Genomics PLC develops algorithms and software solutions that focus on cancer, microbes, and rare diseases. Its solutions allow governments and healthcare providers to transform healthcare provisions for their citizens and members; pharmaceutical and biotechnology clients to de-risk the drug development process; clinicians and doctors to improve diagnoses and treatment options; and research laboratories and genome analysts to process results accurately. The company was incorporated in 2014 and is based in Oxford, United Kingdom.

Avidity Biosciences

Series B in 2018
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

Devoted Health

Series B in 2018
Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technology to enable a simplified experience, and by partnering with top providers for better health outcomes.

PharmEasy

Series C in 2018
PharmEasy is a leading pharmacy aggregator in India that operates an online drug delivery platform aimed at enhancing the supply chain of pharmaceuticals. By digitizing the process, it connects patients with local pharmacy stores and diagnostic centers, ensuring they can easily access a wide range of medicines and healthcare products. The platform is designed to make healthcare services more accessible and affordable, emphasizing the importance of good health for everyone. Through its services, PharmEasy strives to simplify the healthcare experience for patients, allowing them to fulfill their medical needs efficiently.

Axoni

Series B in 2018
Axoni is a New York-based technology firm focused on capital markets, specializing in distributed ledger solutions. Founded in 2013 by experts in distributed ledger technology and cryptography, Axoni serves major financial institutions and capital markets service providers. The company's offerings include the deployment of distributed ledger technology, custom smart contract development, and advanced analytics tools. Their software integrates traditional financial technologies with blockchain capabilities, providing market information and in-depth trend analysis. This comprehensive approach enables investment funders, exchange operators, and professional traders to enhance their systems for managing legal records, lifecycle events, and cash flow calculations.

RiskRecon

Series B in 2018
RiskRecon is the only continuous vendor monitoring solution that delivers risk-prioritized action plans custom-tuned to match your risk priorities, providing the world’s easiest path to understanding and acting on third-party cyber risk. Partner with RiskRecon to build your scalable, third-party risk management program to realize dramatically better risk outcomes. To learn more about RiskRecon’s approach, request a demo or visit the website at www.riskrecon.com.

Radico

Series B in 2018
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.

WelbeHealth

Series B in 2018
WelbeHealth is a healthcare organization dedicated to enhancing the quality of life for frail seniors through the PACE (Program of All-Inclusive Care for the Elderly) model. Founded by experienced physician entrepreneurs, the company provides comprehensive medical and social care, ensuring that participants receive coordinated support that includes medical and dental care, therapy services, transportation, and meal provisions. By focusing on the diverse needs of the elderly population, WelbeHealth aims to help them live longer, healthier, and more independent lives. The leadership team comprises professionals from prominent payer and provider organizations, reflecting a commitment to innovative and compassionate care. Through its holistic approach, WelbeHealth strives to unlock the potential of vulnerable seniors in the community, fostering an environment of empathy and support.

Unison

Series B in 2018
Unison is a provider of home-ownership investments used for long-term financing. Its investments offer long-term investments in individual residential properties through their innovative programs in exchange for the opportunity to share gain or loss in the home's value when they decide to sell that enable applicants to buy homes without interest or monthly payments. It was founded in 2004 and is headquartered in San Francisco, California.

Benchling

Series B in 2018
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.

Tempest Therapeutics

Series B in 2018
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Protenus

Series B in 2018
The Protenus healthcare compliance analytics platform uses artificial intelligence to audit every access to patient records for the nation’s leading health systems. Providing healthcare leaders full insight into how health data is being used, and alerting compliance teams to policy violations, Protenus helps our partner hospitals make decisions about how to better protect their data, their patients, and their institutions. Learn more at Protenus.com and follow us on Twitter @Protenus.

Quartet Health

Series C in 2018
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.

Orchard Therapeutics

Series B in 2017
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Semma Therapeutics

Series B in 2017
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.

Threat Stack

Series C in 2017
Threat Stack specializes in providing security solutions tailored for cloud infrastructure, enabling DevOps and SecOps teams to innovate and scale securely. The Threat Stack Cloud Security Platform and Cloud SecOps Program are designed to address complex cloud security needs by delivering continuous security monitoring and risk assessment. This approach helps organizations identify and verify insider threats, external attacks, and compliance gaps in real-time. By focusing on cloud, hybrid-cloud, and containerized environments, Threat Stack empowers security and operations teams to effectively manage risk and compliance across their entire infrastructure.

Stride Health

Series B in 2017
Stride Health, Inc. operates a health benefits platform that allows independent workers and part-time employees to select and enroll in affordable health coverage. It offers dental plans, drive plans, and doctor and prescription insurance plans. The company serves customers in the United States. Stride Health, Inc. was formerly known as Covered, Inc. and changed its name to Stride Health, Inc. in March 2013. The company was incorporated in 2013 and is based in San Francisco, California.

Artemis Health

Series B in 2017
Artemis Health Inc. is a health data analytics company that focuses on providing self-insured employers with actionable insights into their benefits programs. The company operates a platform that enables users to identify issues within their benefits, share findings with stakeholders, and implement solutions to enhance their offerings while tracking the effectiveness of these solutions. Founded in 2013 and headquartered in Salt Lake City, Utah, Artemis Health aims to improve the healthcare system in the United States by empowering employers to leverage their own benefits data to reduce spending and enhance employee benefits.

Amphora Medical

Series B in 2017
Amphora Medical is a Minnesota-based developer of medical devices and instruments. The company is currently working on a novel cystoscopic device that has the potential to improve bladder function and quality of life for people with Overactive Bladder Syndrome (OAB). It was founded in 2011 and is headquartered in Minneapolis, Minnesota, United States.

VYNE Therapeutics

Series C in 2017
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.

Wellframe

Series B in 2017
Wellframe is a hospital and healthcare it provides a digital health management solutions that include care management support, digital concierge solutions, and transformation services. It helps healthcare organizations by providing solutions that enable them to support people longitudinally between traditional clinical interactions. The company was founded in 2011 and headquartered in Boston, Massachusetts, United States.

Checkmate Pharmaceuticals

Series B in 2017
Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Quovo

Series B in 2017
Quovo Inc. is a data platform that specializes in providing financial analytics and data management solutions primarily for small and mid-sized investors. Founded in 2009 and based in New York, Quovo offers a service that automatically gathers, normalizes, and reconciles portfolio data from a wide range of financial institutions, including retail brokerages and custodians. Its offerings include tools for client onboarding, payment processing, and comprehensive insights into consumer financial accounts from over 14,000 institutions. Quovo's technology features automated data repair, manual entry support, and security measures, enabling clients such as family offices, advisors, and foundations to track investment strategies and generate reports. The company also supports fintech firms and leading financial services providers by enhancing customer relationships through streamlined access to financial data. Quovo operates as a subsidiary of Plaid Inc. since January 2019.

Medwell Ventures

Series B in 2017
Medwell Ventures Private Limited provides specialty home healthcare services in India. It focuses on various therapeutic areas. The company offers various wellness and care programs ranging from preventive screening to home healthcare and palliative care. It provides bedside nursing care at home, as well as 24×7 medical services, such as physician consultation, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, pharmacy support, and related medical services. The company’s integrated healthcare delivery system serves customers across varied age and health profiles. Medwell Ventures Private Limited was founded in 2014 and is headquartered in Bengaluru, India.

Promentis Pharmaceuticals

Series C in 2017
Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, focusing on treatments that address glutamatergic imbalance and oxidative stress. Promentis is advancing compounds such as SXC-2023, which targets System xc- to treat conditions including impulse control disorders and obsessive-compulsive disorder. Additionally, Promentis has intentions to develop a new antipsychotic drug aimed at treating schizophrenia, positioning itself to address significant unmet medical needs in the field of mental health.

Pulmocide

Series B in 2017
Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.